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ORIGINAL ARTICLE
Complications of Allogeneic Hematopoietic Stem Cell Transplantation
Karim Arnaout, Nihar Patel, Maneesh Jain, Joelle El-Amm, Farah Amro, and Imad A. Tabbara
Department of Medicine, Division of Hematology and Oncology, GeorgeWashington University Medical Center, Washington,
USA
Infection, graft-versus-host disease (GVHD), and to a lesser
extent sinusoidal obstructive syndrome (SOS) represent the
major causes of morbidity andmortality in patients
undergoing allogeneic hematopoietic stem cell transplantation
(AHSCT). During the last decade, progress in prevention and
treatment of these complications led to improvement in the
outcome of these patients. Despite the fact that
nonmyeloablative regimens have been increasingly used in
elderly patients and in patients with co-morbidities, the
nonrelapse related mortality remains a challenge and
long-term follow-up is required. The objective of this
manuscript is to provide an updated concise review of the
complications of AHSCT and of the available treatment
interventions.
Keywords: Bone marrow transplant, Leukemias, Long-term
survival and late eﬀects
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (AH-
SCT) is considered a curative treatment option for many
hematologic diseases (1). Acute and chronic leukemias,
myelodysplastic and myeloproliferative syndromes account
for approximately 70% of AHSCT cases in North America
(2). The beneficial effect of this approach is not only due
to the preparative chemo-radiotherapy regimen, but more
importantly due to the immunologic effect induced by graft-
versus-tumor (GVT) (3). Although the number of trans-
plants from related donors has remained stable, unrelated
donors have been increasingly used and currently contribute
to almost 50% of AHSCT cases (4). Several complications
including infection and GVHD have remained the major
causes of mortality and morbidity. These complications are
due to toxicities of the preparative regimen, the accompa-
nying immunodeficiency, and the organ damage induced
by GVHD. In the past two decades, there has been a steady
increase in the use of nonmyeloablative or reduced-intensity
conditioning (RIC) regimens, especially in elderly patients
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and patients with co-morbidities. The treatment benefit of
these regimens relies almost exclusively on the GVT effect.
Several studies have shown improvement in non-relapse
mortality rates due to decreased regimen-related toxicity (4).
Preparative regimens
The conventional preparative regimens have twomajor goals.
The first goal is to provide adequate immunosuppression in
order to prevent rejection of the transplanted graft and the
second goal is to eradicate the underlying disease. The opti-
mal myeloablative conditioning regimen remains unknown.
High-dose oral busulfan combined with cyclophosphamide
(BuCy) and cyclophosphamide in combination with total
body irradiation (CyTBI) are well-established regimens and
represent the two most commonly used conditioning regi-
mens. Several studies have failed to show any difference in
survival between these two regimens (5). However, more re-
cently, intravenous (IV) busulfan conditioningwas compared
to total body irradiation (TBI) in patients with myeloid ma-
lignancies and was associated with superior survival with
no increased risk of relapse or transplant-related mortality
(6). Copelan et al. showed that a conditioning regimen us-
ing a combination of cyclophosphamide with IV busulfan
was associated with better non-relapse mortality, relapse af-
ter one year post transplant, better leukemia-free survival and
survival, compared to CyTBI in AML patients receiving a
first AHSCT (7). Pharmacokinetic targeted IV busulfan com-
bined with fludarabine was retrospectively compared to oral
busulfan in combination with cyclophosphamide in patients
undergoing AHSCT for AML, and was associated with re-
duced conditioning regimen related toxicity (8). Moderate
dose (6.4 mg/kg total dose) IV busulfan was shown to be as-
sociated with lower toxicity and no change in OS compared
to the full dose (12.8 mg/kg total dose) IV busulfan in flu-
darabine/busulfan/ATg RIC regimen (9).
Other regimens combining radiation in combination
with etoposide or high dose cytarabine, with or with-
out cyclophosphamide have also been used (10). Radia-
tion noncontaining regimens were developed in an attempt
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to eliminate the toxicity of radiation. These regimens in-
clude busulfan and etoposide in patients with acute myeloid
leukemia, cyclophosphamide, carmustine (BCNU), etopo-
side, and BCNU, etoposide, cytosine arabinoside and mel-
phalan (BEAM) in lymphomas. Kahl et al. reported that the
survival rate at 9.2 years was 88% in patients with aplastic
anemia conditioned by cyclophosphamide combined with
antithymocyte globulin (ATG) followed by allogeneic mar-
row transplants (11). Radio-labeled monoclonal antibodies
(anti-CD20, anti-CD45, anti-CD66) use was also reported
in small series, allowing the radiation to target the tumor
cells and marrow, and minimizing radiation effects on other
organs.
Common side effects of the preparative regimens in-
clude myelotoxicity, mucositis, nausea and vomiting, diar-
rhea, alopecia, rash, and peripheral neuropathy. Pulmonary
and hepatic toxicities are also relatively common especially
with busulfan. Cyclophosphamide is associated with an in-
creased risk of renal toxicity (12). Recent studies have fo-
cused on the development of nonmyeloablative or RIC reg-
imens. The main aim is to exploit the beneficial GVT effect
and reduce regimen-related complications (13). Fludarabine
in combination with busulfan, melphalan or low dose irra-
diation has been widely studied and has shown promising
results (14, 15). Total lymphoid irradiation (TLI) with ATG
also showed reduction in acute GVHD risk with retention of
GVT effects (16). Comprehensive reviews of the role of non-
myeloablative therapy in AHSCT have been previously pub-
lished (17, 18).
Immunologic and infectious complications
Deficiencies in the cellular as well as humoral aspects of
the immune system occur to some extent in all AHSCT pa-
tients for a variable period of time. However, in patients
with GVHD receiving immunosuppressive therapy, these de-
ficiencies are more profound and prolonged (19). Cellular
immunodeficiency is a result of a lowered T-cell response
to alloantigens and mitogens, decreased helper CD4+ cell
function and reactivity to intradermal skin tests. Humoral
immunodeficiency consists of a decrease in both IgG2 and
IgG4. However, immunoglobulin levels may be within the
reference range. The switch fromprimary (IgM) to secondary
(IgG) production as well as antigen-specific responses is ab-
normal, leading to an impaired production of antibodies
to pathogens. The recovery of the immune system consists
of two phenomena, innate immunity or the numerical re-
covery of hematopoietic cells and adaptive immunity, the
functional recovery of cellular interactions (19). Because of
thymic involution in adult patients, T-cell function is de-
pendent upon the peripheral expansion of the few donor
T-cells that are present in the graft. Immune reconstitution
is usually slow in adult patients reaching normal level 2 to
3 years after transplant. This is in contrast to immune re-
constitution in children where cell function and T-cell re-
ceptor repertoire recover within the first 1 to 1 12 years after
transplant (20).
Infectious complications of AHSCT are summarized in
Table 1. Viral infections are major causes of morbidity and
mortality in AHSCT recipients. Infections caused by the her-
pes virus group are common and are usually a consequence
of reactivation of a latent virus. Infectionwith the herpes sim-
plex virusmay occur 1 to 2weeks after transplantation in 80%
of seropositive patients who are not receiving acyclovir pro-
phylaxis, causingmuco-cutaneous lesions of the oropharynx,
esophagus, or genital tract (21–23). Other viruses, including
varicella-zoster, respiratory syncytial virus, para-influenza
virus type 3, human metapneumovirus, human herpes virus
6 and 8, and Epstein-Barr may also cause pulmonary
infections.
Cytomegalovirus (CMV) is the most common viral
pathogen associated with respiratory tract infections
(24–26). CMV infection can be the result of a primary
infection or a reactivation of the virus. It tends to occur
4 to 10 weeks after transplantation (22). Prophylaxis and
empirical treatment lead to a significant decline in the rate
of infections to less than 5% (27–29). Despite a reduction in
CMV pneumonia in the early post-transplantation period,
it continues to be a significant cause of morbidity and
mortality in the later post-transplant period. Risk factors
include older age, positive CMV serology, allogeneic graft
and acute GVHD (30–34). Given the more liberal use of
prophylactic therapy, CMV pneumonia can now occur later
than 100 days after transplant (35, 36).
Prevention of CMV infections relies on the use of CMV-
negative blood products in CMV-seronegative donor-patient
pairs (37), intravenous immunoglobulin (38, 39), pre-storage
of leukocyte-depleted blood products, leukocyte-filtered
blood products, and prophylactic antiviral agents. Three ran-
domized, placebo-controlled studies have shown that the
prophylactic use of ganciclovir led to a significant reduction
in the incidence and severity of CMV infections in CMV-
seropositive AHSCT recipients (40–42).
Foscarnet sodium was used prophylactically in a small
phase I-II study in CMV-seropositive patients (43). In
this study, starting foscarnet 7 days before the trans-
plant and continuing it for 75 days after transplanta-
tion was effective in preventing CMV infections in most
patients.
CMV prophyalaxis has been replaced with a pre-emptive
strategy based upon active screening for CMV. Previ-
ously utilized antigenemia assays guiding institution of pre-
emptive therapy, has been supplanted by real time poly-
merase chain reaction (PCR) tests for the quantification of
CMVDNA. PCR tests have been shown to be more sensitive
and particularly adept in patients with low cell counts or in
which specimens need to be stored or shipped (44).
CMX001 is an orally bioavailable, lipid acyclic nucleoside
phosphate that is absorbed and converted intracellularly to
cidofovir diphosphate. In a multi-center trial, treatment with
CMX001 at a dose of 100 mg twice weekly, in sero-positive
CMV patients undergoing AHSCT, was shown to signifi-
cantly lower the incidence of CMV events from 27% to ap-
proximately 10%. Myelosuppresion and nephrotoxicity were
not observed (45).
Over the years, given the improvement in prevention as
well as treatment of bacterial infections, fungi have become
Cancer Investigation
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Table 1. Infectious Complications of Allogeneic Hematopoietic Stem Cell Transplantation
Pre-engraftment: Early (<3 weeks) Postengraftment: Immediate (<3 weeks–3 months) Postengraftment: Late
Bacterial Gram positive cocci
Gram negative bacilli
Anaerobes
Gram positive cocci
Gram negative bacilli
Anaerobes
Encapsulated
Fungal Candida spp.
Aspergillus spp.
Aspergillus spp.
Pneumocystis carinii
Candida spp.
Aspergillus spp.
Pneumocystis carinii
Viral HSV 1,2
RSV
Influenza
Adenovirus
Cytomegalovirus
HHV 6
RSV
Influenza
Adenovirus
VZV
EBV
RSV
Influenza
Adenovirus
the foremost infectious cause of morbidity and mortality
in AHSCT patients (46). Risk factors associated with in-
creased susceptibility to late fungal infections in patients
with chronic GVHD include impaired mucosal defense,
chemotactic defects, functional asplenia, and qualitative and
quantitative B- and T-cell abnormalities. Late-onset fungal
infections with invasive candidiasis and aspergillosis can
occur several months after transplantation, especially in
patients with severe GVHD receiving immunosuppressive
therapy.
Prevention of fungal infections is clearly preferred due
to the difficulty in treating established infections. Multiple
agents have been utilized to prevent invasive fungal infections
in AHSCT recipients, including azoles as well as echinocan-
dins. Prophylactic therapy with fluconazole, 400 mg/day, is
associated with fewer positive fungal cultures, systemic fun-
gal infections, and improvedmortality (47, 48). In a random-
ized, double-blind trial, posaconazole prophylaxis was found
to be superior in preventing invasive aspergillosis and re-
ducing the rate of deaths related to fungal infections (49).
Though relatively well tolerated, liver function tests should
be monitored at baseline and throughout posaconazole ther-
apy and treatment should be discontinued if serious hep-
atic abnormalities occur. Other rare serious adverse events
that were reported in this study include hemolytic uremic
syndrome, thrombotic thrombocytopenic purpura, and pul-
monary embolus. Prolongation of the QT interval may be
seen with posaconazole as well as with the other azole an-
tifungal agents.
Invasive aspergillosis has been reported to occur in 3.6 to
28% of patients (50). Patients generally present with nonspe-
cific symptoms including, fever, productive cough, and pleu-
ritic chest pain (51, 52). Radiographic findings including the
“halo sign” which corresponds to a nodule surrounded by
ground-glass attenuation and the “hypodense sign” which re-
flects the presence of low density within nodules or areas of
consolidation, are reported to have 30% sensitivity and 100%
specificity for the diagnosis of invasive pulmonary aspergillo-
sis (53).
Targeted screening for markers of fungal colonization, in
attempt to prevent invasive infection, is being utilized fre-
quently. Available tests include, Aspergillus PCR of serum,
(1–3)-β-D-Glucan and/or the galactomannan antigen (GAL)
assay (54). Initiation of therapy should be considered in pa-
tients at high risk with positive screening tests. The drug of
choice for invasive aspergillosis is voriconazole, which has
been shown to lead to better responses and improved survival
with fewer side effects in comparison to the old standard ap-
proach using amphotericin B deoxycholate (55).
After invasive aspergillosis, pathogens of mucormycosis
are the second most common cause of mold infections, and
can lead to life threatening rhino-orbital, pulmonary, cere-
bral, or disseminated infection (56). Treatment involves com-
bination of surgical debridement and antifungal therapy,with
intravenous liposomal amphotericin B remaining the drug
of choice. Unfortunately, prognosis for recovery from mu-
cormycosis remains poor (56, 57).
PCP (Pneumocystis Carinii Pneumonia) infection has
decreased dramatically with the use of trimethoprim-
sulfamethoxazole (TMP-SMZ) prophylaxis. For patients in-
tolerant to TMP-SMZ, alternative treatments for prophylaxis
include atovaquone, dapsone, or aerosolized pentamidine
(58).
Sinusoidal obstructive syndrome
Sinusoidal obstructive syndrome (SOS), known in the past
as veno-occlusive disease of the liver, is seen in about 10% of
patients receiving myeloablative conditioning regimens (59).
More recently, the use of intravenous busulfan-based regi-
mens in conjunction with reduced intensity conditioning has
resulted in a significant decline in the rate of SOS (60, 61).
A definitive incidence is difficult to estimate due to differ-
ences in regimens as well as supportive care amongst trans-
plant centers, though one large series showed an overall rate
of about 5% (62).
With no established laboratory, imaging, or histologic test,
SOS remains an elusive diagnosis. Most patients are diag-
nosed within 3 weeks of AHSCT. Clinical symptoms include
jaundice, tender hepatomegaly, fluid retention and weight
gain. In some cases, SOSmay occur at the same time as acute
GVHD,making clinical differentiation between the two con-
ditions difficult. The pathogenesis of SOS remains unclear.
One of the etiologies is thought to be the obstruction of the
terminal hepatic and sublobular central venules by endothe-
lial cell injury and thrombosis, leading to a shift of fluid con-
taining sodium and albumin from the intravascular to the ex-
travascular space. This fluid shift leads to a decrease in renal
blood flow and activation of the renin-angiotensin system,
resulting in sodium and fluid retention. An early decrease in
Copyright C© 2014 Informa Healthcare USA, Inc.
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protein C and antithrombin III levels may play a role in the
pathogenesis of SOS and is predictive of its development and
severity (63).
Transjugular liver biopsies andmanometricmonitoring of
hepatic blood flow can help in establishing the diagnosis of
SOS (50, 51). Less invasive tests such as plasminogen activa-
tor inhibitor-1, an inhibitor of the fibrinolytic system, can be
useful, when elevated, in ruling out SOS with a high sensi-
tivity (100% in one study) (64). Patients with mild disease,
as evidenced by minimal elevation in the bilirubin level and
mild weight gain, have an excellent prognosis. In contrast,
patients who have a bilirubin level of 20 mg/dL or higher
(>342 μmol/L) or a weight gain of 15% or more of original
weight have 90% mortality before day 100 (65).
There has been no established therapy of SOS. Alteplase
and heparin therapy have been historically associated with a
modest response rate of approximately 30%, but severe bleed-
ing rates of 25% were reported with these drugs (66).
The most promising agent, defibrotide, is an oligonu-
cleotide derived from porcine tissue that has antithrombotic,
thrombolytic, anti-ischemic and anti-inflammatory proper-
ties, and an affinity for small vessels. It was shown to have lit-
tle systemic anticoagulant activity compared to alteplase and
heparin. Initial studies showed that the use of defibrotide, in
patients with severe SOS, induced complete response rates of
36–55% with 35–53% survival at day 100 (67, 68).
In the largest prospective evaluation of defibrotide for the
treatment of severe SOS and multiorgan failure, data from
an interim analysis, based on 269 patients, revealed that 32%
achieved a CR and 50% survived to day 100. Toxicity proved
to be manageable with 22% of patients experienced a total of
81 relatedAEs, primarily consisting of bleeding and hypoten-
sion. Defibrotide was given at a dose of 6.25 mg/kg IV q6h
with treatment duration recommended for at least 21days
(69).
Given the ambiguity of diagnosis as well as costly and
modest therapeutic response rates, prevention remains the
most effective tactic in managing patients at risk for SOS.
The risk factors for developing SOS include pretransplant ele-
vation of serum aminotransferase levels (especially aspartate
aminotransferase), intensive conditioning therapy (higher
TBI and busulfan dose), graft from a mismatched or un-
related donor, and use of antimicrobial therapy with acy-
clovir, amphotericin B, or vancomycin (58). Sodium and
fluid restriction and the judicial use of diuretics remain the
main preventive approaches for this condition (70). Pen-
toxifylline, a xanthine derivative capable of downregulat-
ing tumor necrosis factor production, has been shown in
randomized studies to be of no benefit in reducing the
incidence of SOS (71–73). A randomized trial showed that
use of low-dose heparin (100 U/kg/d) was capable of re-
ducing the incidence of SOS without added risk of bleed-
ing (74). Ursodiol administration reduced the incidence of
SOS in a randomized, double-blind, and placebo-controlled
trial in patients receiving a preparative regimen of cyclophos-
phamide and busulfan (75).
In a report of 58 patients who received defibrotide as pro-
phylaxis without concurrent heparin or ursodiol, no patients
fulfilled the criteria for SOS or died of the condition within
100 days of AHSCT. In this study, patients received 5 mg/kg
of intravenous defibrotide over 2 hr, twice-daily from day+1
to +21 (76).
Finally, minimizing liver insults by removing any hepato-
toxic medication should be attempted at all time.
Graft-versus-host disease
Graft-versus-host disease (GVHD) remains one of the ma-
jor causes of morbidity following AHSCT leading to pro-
longed use of immunosuppressive agents, organ dysfunction,
increased risk of infection, and ultimately increased mortal-
ity (77).
Acute GVHD
The occurrence of acute GVHD has been defined histori-
cally to be limited to the first 100 days following AHSCT
(78). However, a clear distinction can no longer apply due
to the increased use of nonmyeloablative regimens and DLI
both of which can potentially delay the appearance of acute
GVHD. In 2005, a group at the NIH published criteria for
the designation of acute and chronic GVHD as follows (79):
Classic acute GVHD occurring within the first 100 days after
AHSCT and persistent, recurrent or late-onset acute GVHD
occurring more than 100 days after transplant both requir-
ing the presence of acute features and absence of chronic
features.
Early research provided insight into the immunologic fac-
tors essential to the development of GVHD and was summa-
rized in Billingham’s postulates in 1996 (78). The graft must
contain immunocompetent lymphocytes, the recipient must
be incapable of immunologically destroying the graft and the
recipient must express antigens that are not present in the
donor, leading to stimulation of the donor lymphocytes. In-
deed, the greater the disparity in the minor and major his-
tocompatibility antigens between the donor and the recipi-
ent, the greater the incidence and the severity of acuteGVHD
(80–82). Despite full HLA-matching between the patient and
the donor, the incidence of acute GVHD still ranges between
26 and 32% in recipients of sibling donor grafts and between
42 and 52% in recipients of unrelated donor grafts (83). Risk
factors for the development of acute GVHD other than the
extent of HLA disparity include increased age of both the
recipient and the donor, gender disparity (with multiparous
female donors carrying particularly a higher risk), ineffec-
tive GVHD prophylaxis and the intensity of the transplant
conditioning regimen (84–86). A risk model for clinical out-
come of AHSCT including acute GVHD based on multiple
single-nucleotide polymorphismwas recently developed and
reported (87). Also, a recent large retrospective study investi-
gated risk factors that have a predictive value for acuteGVHD
(88). Results of this study indicated that regimens that do not
use TBI are associated with lower risk for acute GVHDwhen
bone marrow and not when peripheral blood was used as
the stem cell source. Biomarker combinations that include re-
generating islet-derived 3-alpha (Reg3alpha), tumor necrosis
factor receptor 1 (TNFR1), Il2 receptor alpha, Il8, hepatocyte
growth factor, and elafin appear to have predictive value for
Cancer Investigation
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Table 2A. Staging of Acute Graft-versus-Host Disease
Clinical stage Lower GI Upper GI Liver (Bilirubin mg/dL) Skin
1 Diarrhea <500 mL/d Nausea/Vomiting 2–3 Rash < 25% of BSA
2 Diarrhea 500–1000 mL/d 3–6 Rash 25–50% of BSA
3 Diarrhea 1000–1500 mL/d 6–15 Generalized erythroderma
4 >1500 > 15 Bullae/Desquamation
Weisdorf D (2006, November). Graft versus Host Disease andHow to Report it. Retrieved April 17, 2014, from http://www.cibmtr.org/Meetings/Materials/CRPDMC/Documents/
2006/november2006/Weisdorf2 RprtgGVHD.pdf
etiology, response to treatment and treatment-related mor-
tality in acute GVHD (89, 90).
Clinical manifestations of acute GVHD include specific
derangements in the skin, the liver and the gastrointesti-
nal tract. With the use of high-intensity conditioning, acute
GVHD most commonly occurs 2 to 42 weeks after stem-
cell infusion. A hyperacute form of GVHD can occur within
the first 2 weeks of AHSCT, and is usually due to significant
HLA mismatch or inadequate GVHD prophylaxis, and can
be rapidly fatal (91).
Acute GVHD is clinically graded and staged in sever-
ity from grades I to IV depending on the extent of skin,
liver, upper GI tract and gut involvement. A commonly used
staging and grading systems are shown in Tables 2A and
2B. The most common and the first organ to be affected
by acute GVHD is the skin. Early cutaneous manifestations
of acute GVHD could be palmar erythema and erythema-
tous discoloration of the face and ears, followed by diffuse
patchy erythema with follicular prominence, and a general-
ized morbilliform eruption. In severe cases, it can progress
to a diffuse erythoderma with bullae formation and desqua-
mation resembling Stevens-Johnson syndrome and toxic epi-
dermal necrolysis (92). Histologically, vacuolar degeneration
and lymphocytic infiltration involving the basal cell layer is
seen in mild disease, and this picture changes to necrotic
dyskeratotic cells with acantholysis and cell membrane sep-
aration in moderate disease. Epidermolysis can develop in
severe cases (93). These findings are not pathognomonic of
GVHD since chemo-radiotherapy and use of other drugs can
induce similar changes. Upper GI symptoms including nau-
sea and vomiting, and lower GI symptoms including abdom-
inal pain and massive watery or bloody diarrhea, along with
laboratory elevation of the bilirubin, alkaline phosphatase
and aminotransferase levels characterize intestinal and hep-
atic involvement. Patients with upper GI tract involvement
have a better response to immunosuppressive therapy com-
pared to patients with involvement of other areas of the gut.
Table 2B. Grading of Acute Graft-versus-Host Disease
Overall Clinical
Grade GI Upper GI Liver Stage Skin Stage
I 0 0 0 1–2
II 1 1 1 3
III 2–3 2–4 –
IV 4 – 4
Weisdorf D (2006, November). Graft versus Host Disease and How
to Report it. Retrieved April 17, 2014, from http://www.cibmtr.org/
Meetings/Materials/CRPDMC/Documents/2006/november2006/Weisdorf2 Rprtg
GVHD.pdf
Failure of these patients to respond to treatment predicts pro-
gression to lower GI involvement (94, 95).
The diagnosis of acute GVHD can be made on clinical
grounds only in patients presenting with a rash, diarrhea
and elevation of bilirubin within the first several weeks of
transplant. However, the diagnosis is frequently not straight-
forward. Mimickers of cutaneous GVHD include toxic ery-
thema of chemotherapy, morbilliform drug eruptions or vi-
ral infections. The differential diagnosis of liver involvement
with GVHD includes VOD, infectious hepatitis and drug-
induced liver toxicity. Parasitic, viral and bacterial infections
can present with similar gastrointestinal symptoms. The role
of skin biopsies in diagnosing acute cutaneousGVHD is con-
troversial as many studies showed the difficulty differentiat-
ing it from its mimickers (96–98).
In patients with isolated hepatic derangement, a liver
biopsy is needed to confirm the diagnosis when it is
deemed safe to perform and the histologic findings on liver
biopsy include lymphocytic infiltration mostly of the por-
tal triad with presence of hepatocellular necrosis some-
times similar to acute hepatitis. Rectal punch biopsies
show epithelial cell necrosis, vacuolar degeneration, crypt
dropout and in advanced cases, epithelial denudation. More
recently, it has been proposed that a panel of plasma
biomarkers including IL-2-receptor-a, TNF receptor-1, IL-
8, and hepatocyte growth factor can confirm the diag-
nosis of acute GVHD at the onset of clinical symptoms
and provide prognostic information independent of GVHD
severity (99).
Prevention is an essential approach in the management of
acute GVHD. The most commonly used pharmacologic reg-
imen includes a combination of a calcineurin inhibitor (cy-
closporine or tacrolimus) and prednisone with a short course
of methotrexate. This regimen was initially established in
1986 (100). Several studies have compared the effectiveness
of this combination with either agent alone and showed su-
periority in prevention of acute GVHD in the combination
arm (101, 102). In a phase III study of patients receiving
an HLA-identical sibling bone marrow graft, prophylactic
therapy with tacrolimus in combination with methotrexate
was shown to reduce the incidence of grade II to IV acute
GVHD compared with cyclosporine and methotrexate ther-
apy. In this study, there was no difference in the incidence of
grade III or IV acute GVHD, chronic GVHD, relapse rates,
or disease-free survival (DFS) or overall survival in patients
with nonadvanced hematologic malignancy. However, there
was a higher frequency of deaths caused by regimen related
toxic effects in patients with advanced disease who received
tacrolimus (103). Tacrolimus-MTX has been compared to
Copyright C© 2014 Informa Healthcare USA, Inc.
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cyclosporine-MTX in another phase III study involving un-
related donors. The Tacrolimus arm demonstrated decreased
incidence of grade II-IV acute GVHD but no overall survival
advantage (104).
The optimal prophylactic regimen following reduced-
intensity HSCT is yet to be established. A commonly
used regimen in this setting includes a combination of a
calcineurin inhibitor with mycophenolate mofetil (MMF)
instead of methotrexate as some studies showed less mu-
cositis and more rapid neutrophil engraftment with MMF
compared to methotrexate (105). Some centers utilize T-cell
depletion which has significantly reduced the incidence
and severity of GVHD but has not gained wide acceptance
because of the increased risk of graft rejection and relapse of
leukemia and therefore no improvement in survival (106).
The best evidence for in vivo antibody efficacy is for ATG
in unrelated HSCT after myeloablative conditioning (107).
In a randomized trial, patients were assigned to receive
cyclosporine and methotrexate with or without anti-Jurkat
rabbit ATG. ATG recipients had a significant reduction of
grade II-IV acute GVHD. Another pharmacological ap-
proach for prevention of acute GVHD is through the use of
sirolimus, an mTOR inhibitor as an addition to methotrexate
and tacrolimus (108). However, due to increased risk of
veno-occlusive disease, sirolimus should not be combined
with myeloablative doses of busulfan or in the TBI-based
myeloablative regimens if combined with methotrexate
(109).
There are many new preventive strategies that are cur-
rently under investigation. One study examined the use of
the CCR5 antagonist Maraviroc (110). In this study, 35 high-
risk AHSCT recipients had a cumulative incidence of grade
2–4 acute GVHD of 14.7% on day 100 and 23.6% on day 180.
The cumulative incidence of grade 3–4 GVHD on day 180
was 5.9%, that was mainly attributed to a very low incidence
of visceral GVHD. At 1 year, the rate of nonrelapse mortal-
ity was 11.7% and rates of relapse or infection were not in-
creased.
Another novel preventive approach is the post-transplant
administration of high-dose cyclophosphamide in an at-
tempt to eradicate activated T cells (111). A study by
the Johns Hopkins University investigators tested the use
of cyclophosphamide as the only prophylaxis for GVHD
after HLA-matched related and unrelated donors T cell-
replete AHSCT (112). When cycloposphamide is given
early after transplantation, it depletes dividing alloreac-
tive T cells rapidly. Aldehyde dehydrogenase, which is
present at high levels in hematopoietic stem cells, convert
4-hydroxycylophosphamide into a nonalkylating metabolite,
sparing the stem cells from the antiproliferative effect of
the drug. Cyclophosphamide was given on days 3 and 4 af-
ter AHSCT without the addition of an immunosuppressive
agent. The results showed that, without the use of colony-
stimulating factors, the median time to neutrophil engraft-
ment was 23 days in the matched related donor group and
25 days in the unrelated donor group. The treatment-related
mortality at 2 years was 13% in the matched related group
and 21% in the matched unrelated group. There was a low
cumulative incidence of chronic GVHD of 10%. The inci-
dence of grade II-IV acute GVHD was 42% and 46% in the
related and unrelated groups respectively with grade III and
IV occurring in 12% and 8% respectively. A major advantage
to the use of cyclophosphamide is the selective elimination
of host-reactive donor lymphocytes rapidly after transplan-
tation, and the rapid immunologic recovery without the use
of calcineurin inhibitors.
The treatment of acute isolated grade II cutaneous GVHD
includes topical corticosteroids or tacrolimus (113). For acute
grade III-IV GVHD, treatment includes high dose systemic
steroids, cyclosporine, and antithymocyte globulin. Forty to
50% of patients respond to steroids and this response is pre-
dictive of prognosis and outcome as there is no well estab-
lished second line therapy. Salvage therapy is under investi-
gation and includes novel pharmacologic agents (e.g., HDAC
inhibitors, proteasome inhibitors, antibodies targeting IL-21,
or adhesion molecules) or upcoming cellular therapeutics
such as Treg, NKT, MSC, or B-cell targeting (114). Patients
with acute GVHDhave a lower incidence of leukemia relapse
owing to a presumed GVL effect (3).
Chronic GVHD
Chronic GVHD remains the most common late complica-
tion of AHSCT. It occurs in almost 50% of patients sur-
viving more than 1 year posttransplant (115). The median
time at presentation is 4 to 6 months after the transplant
(116). Chronic GVHD is divided into two subtypes: clas-
sic GVHD (without features characteristic of acute GVHD)
and overlap syndrome (with synchronous clinical features)
(88). Risk factors include high degree of HLA mismatch-
ing, old age, gender disparity of donor and/or recipient,
prior acute GVHD, cytomegalovirus seropositivity (donor
and recipient) and the use of peripheral blood precursor
cells (117). A recent phase 3, multicenter, randomized trial
of transplantation of peripheral-blood stem cells versus bone
marrow from unrelated donors showed no significant dif-
ference in survival. Peripheral-blood stem cell transplanta-
tion may reduce the risk of graft failure. On the other side,
bone marrow transplantation may reduce the risk of chronic
GVHD (118).
The pathogenesis is still poorly understood. Thymic atro-
phy, lymphocyte depletion and autoantibody formation have
been described. Current evidence suggests that disruption of
thymic function by conditioning regimens and acute GVHD
leads to dysregulation of the negative selection process of po-
tentially autoreactive T-lymphocytes. Disregulated autoreac-
tive T-cells will then activate autoreactive B-cells, which leads
to autoantibody production and causes target organ damage.
The continuous presence of T-helper 2 cells is required in
chronic GVHD, and the role of interleukins, especially (IL)-
12 and (IL)-18, has been demonstrated in murine models
(119).
Chronic GVHD has similar clinical features to autoim-
mune diseases. The most common affected organ is the skin
(lichen planus or scleroderma cutaneous manifestations).
Other common target organs are the liver (bile duct damage
with cholestasis), the gastrointestinal tract (erythema with
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lichenoid lesions of the buccal and labial mucosa, ulcera-
tion and malabsorption), the lungs (bronchiolitis obliterans
which may be associated with pulmonary failure and in-
creased mortality) and the musculoskeletal system (fasciitis,
stiffness and contractures) (120, 121). Diagnosis requires his-
tologic confirmation which is usually by biopsy of the skin,
mouth or liver.
There is no effective prophylaxis against chronic GVHD
due to incomplete understanding of the pathophysiology of
the disease (121). The risk may be reduced by selecting a
younger, related male donor; using bone marrow rather than
peripheral blood stem cells; and possibly limiting the infused
doses of CD34+ and T-cell. Kottaridis et.al studied a non-
myeloablative preparative regimen, using CAMPATH-1H at
a dose of 20 mg/day on Days –8 to –4, fludarabine 30 mg/m
(2) on Days –7 to –3 and melphalan 140 mg/m (2) on Day
–2, in 44 patients with hematologic malignancies. This ap-
proach was associated with durable engraftment, minimal
toxicity and low incidence of GVHD. At a median follow-up
of 9 months, only one patient was reported to have chronic
GVHD (122). Hale et al. showed that the incidence of chronic
GVHD was 3% in AML patients in first remission who were
transplanted from HLA-identical siblings and where donor
cells were incubated in vitro with Campath-1M. In this study,
Campath-1G was infused in vivo before donor cell infusion,
and no post-AHSCT immunosuppression was given (123).
Barge et al, showed that the incidence of chronic GVHD
was 19% in 73 patients who received myeloablative regimen
and a transplant from HLA-identical siblings and received
donor cells treated in vitro with Campath-1M (124). High-
dose post-transplantation cyclophosphamide was also sug-
gested to be an effective single-agent prophylaxis of acute and
chronic GVHD in patients with advanced hematologic ma-
lignancies after BuCy conditioning and HLA-matched BMT
(125). Data suggest that an anti-CD6 antibody plus comple-
ment for in vitro T-cell depletion resulted in an incidence
of chronic GVHD of less than 15% in HLA-identical sibling
transplants (126).
Patients with limited disease may not need systemic ther-
apy. However, for patients with extensive involvement, im-
munosuppressive therapy consisting of alternating pred-
nisone and cyclosporine has been shown to increase the
overall survival and has been the standard first line ther-
apy. Doses are usually tapered over time and the median
duration of therapy is usually 2–3 years. Steroid-refractory
patients should be entered in clinical trials. Extracorpo-
real photopheresis, mTOR inhibitors including sirolimus and
tacrolimus, rituximab, pentostatin, and imatinib are sug-
gested as second line treatment options in refractory chronic
GVHD. MMF, methotrexate, and pulse corticosteroids are
considered for third line therapy (127). Mortality in chronic
GVHD is largely due to infection, especially in the setting
of immunosuppression. Therefore, all patients should receive
antimicrobial prophylaxis against PCP and encapsulated or-
ganisms.
Poor prognostic factors include extensive skin involve-
ment (>50%), thrombocytopenia (<100,000/uL), and pro-
gressive onset chronic GVHD without resolution of acute
GVHD. Other risk factors for poor outcome include old age,
poor performance status, and hyperbilirubinemia (128).
GRAFT FAILURE
Graft failure is a life threatening complication that occurs oc-
casionally following AHSCT. It can be early, as evidenced by
lack of initial hematopoietic recovery, or late, in association
with recurrence of the disease or reappearance of host cells af-
ter initial donor cell engraftment. The incidence of graft fail-
ure following AHSCT is below 5% (103). Risk factors include
donor-recipient HLA or ABOmismatch, unrelated donor al-
loantibodies, less intense conditioning regimen, T-cell deple-
tion, insufficient number of transplanted stem cells, and viral
infections such as CMV infection (129, 130).
The pathophysiologic characteristics of failure of sus-
tained and complete engraftment are not completely un-
derstood. There is some evidence to suggest that graft fail-
ure may result from a graft-versus-marrow effect or from
an abnormal microenvironment (131). It is important to
differentiate between graft failure and severe marrow sup-
pression secondary to infections (CMV), administration of
certain drugs (Ganciclovir), and chronic GVHD causing
thrombocytopenia.
Management of graft failure includes augmentation by
hematopoietic growth factors, administration of additional
hematopoietic stem cells, and second transplantation with
pre-infusion conditioning (129). Bone marrow or periph-
eral blood stem cells from the original donor or another
donor may serve as the additional AHSCT. In a retrospec-
tive study looking at 82 patients with acute leukemia, aplastic
anemia, or chronic myeloid leukemia who underwent a sec-
ond transplant, the engraftment rate was 73% with a day-100
transplant-related mortality of 50% (132). Although the effi-
cacy of a second transplant has been shown in some patients,
the best source of AHSCT (bone marrow versus peripheral
blood) remains unclear (133).
RELAPSE RISK
Relapse rates after AHSCT vary by disease type, disease sta-
tus at transplantation, and by the presence of GVHD. For pa-
tients withAML/MDS, the relapse rate ranges from20 to 90%
(134, 135). The detection of minimal residual disease (MRD)
from the peripheral blood and bone marrow has been shown
to be a predictor of outcome in ALL, AML, and CML (136).
When relapse occurs after AHSCT, the prognosis is usually
poor (137, 138). The standard initial intervention, once dis-
ease recurrence has been identified, is reduction or discon-
tinuation of immunosuppressive therapy. This approach has
induced remission rates ranging from 84% in chronic phase
CML, to 10% in AML, and 0% in ALL (139). In patients
with acute and chronic leukemia, the duration of remission
after the first transplant appears to be the most important
prognostic factor (140, 141). More favorable outcomes are
also seen in patients who achieve complete remission before
a second AHSCT (140, 141). Two prospective studies have
evaluated the strategy of reduction of disease burden with
Copyright C© 2014 Informa Healthcare USA, Inc.
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chemotherapy followed by granulocyte colony stimulating
factor-primed DLI in patients with advanced myeloid malig-
nancies (142, 143). Patients in remission lasting greater than
6months had a greater likelihood of response. The efficacy of
DLI was retrospectively studied in patients with AML in first
relapse after AHSCT (144). Benefit of DLI was seen in a mi-
nority of patients, including those with a lower tumor burden
at relapse (<35%BMblasts), female sex, favorable cytogenet-
ics, and remission before DLI. Low dose azacitidine, prior to
DLI or second AHSCT, has been used to decrease the tumor
burden especially in AML patients withMRD following AH-
SCT (145).
Other studies suggested that the use of prophylactic/
maintenance azacitidine, following AHSCT, may help pre-
vent relapse in high risk AML patients by augmenting GvL
effect without increasing GVHD. Hypomethylating agents
were also found to be beneficial as salvage treatment for AML
patients who relapsed following AHSCT (146). Treatment
with either azacitidine or decitabine was shown to induce
a CR in 75% of patients with relapsed AML or with loss of
donor chimerism (LDC) after AHSCT for both AML and
high-riskMDS patients (147). A study using Low-dose azaci-
tidine as amaintenance or salvage treatment after AHSCT for
patients with AML/MDS showed a one year overall survival
rate of 90% (145).
A second AHSCT should be considered in selected pa-
tients whose duration of remission is more than 6 months
after the first HSCT. The choice of second HSCT versus
DLI should be individualized on the basis of donor avail-
ability and achievement of remission before DLI or second
HSCT.
LATE COMPLICATIONS
Several delayed complications after AHSCT can occur and
require long-term follow-up (Table 3). The use of TBI and
chemotherapy as part of the conditioning regimen prior
to AHSCT can induce secondary malignancies. This is at-
tributed to the mutagenic risk of irradiation and chemother-
apy, the genetic predisposition of the patient to develop can-
cer, prolonged immunosuppression, and an age-related risk
for elderly patients.
A large report, including more than 1000 patients trans-
planted before December of 1985, showed that the incidence
of secondary malignancies is around 3.5% at 10 years and
12.8% at 15 years, which is a 3.8-fold higher than that of an
age-matched control population (148). A recent update on
the study demonstrated that the incidence of secondary ma-
lignancies continues to increase with longer follow-up time
compared to the control population (149). Another large
analysis, which included 28,874 patients showed that solid
tumors are twice more frequent than expected in the general
population (150). This risk reached threefold among patients
followed for 15 years or more. In a study including acute
and chronic myeloid leukemia patients receiving high-dose
busulfan and cyclophosphamide conditioning, the cumula-
tive incidence of solid cancers at 10 years was 1.2% for acute
myeloid leukemia, which was 1.4 times higher than the ex-
Table 3. Late Complications
Secondary
malignan-
cies
Increased incidence for tumors of the oral
cavity, esophagus, lung, breast, soft tissue,
and brain.
Reproductive Infertility in men and women.
Endocrine Clinical hypothyroidism, osteoporosis
Cataracts
Pulmonary Obstructive pulmonary defects.
Bronchiolitis obliterans.
Liver Hepatitis B and hepatitis C infections
leading to fulminant hepatitis or
cirrhosis.
Hematologic Iron overload.
Neurologic Leukoencephalopathy.
Cerebellar ataxia and seizures.
Motor spinal cord syndromes.
pected rate (132). Significantly elevated risks were observed
for tumors of the oral cavity, esophagus, lung, soft tissue, and
brain (151). A joint EBMT/Seattle study revealed that the cu-
mulative incidence of breast cancer is around 5% at 20 years
and the median time to breast cancer diagnosis is around
12.5 years (152). Cumulative incidence was higher among
survivors who received TBI than those who did not receive
TBI. Lifelong surveillance is important as secondary malig-
nancy rates increase over time after AHSCT and is greater
among younger patients.
Most men and women treated with TBI become infertile,
and although a fewwomenwere reported to have been able to
become pregnant, recovery of spermatogenesis in men is un-
likely. However if high dose cyclophosphamide is used alone,
many women younger than 25 years experienced recovery
of ovarian function and most men experienced recovery of
spermatogenesis (153).
Clinical hypothyroidism is another late complication that
can occur as early as 1 year and as late as 15 years after AH-
SCT. The use of glucocorticoids to treat GVHD is associated
with an increased incidence of cataracts. In a large series
evaluating a cohort of 1064 patients, factors independently
associated with an increased risk of cataracts were older age,
highest dose rate of TBI, AHSCT, and steroid administration
(154). Obstructive pulmonary defects can happen in 10%
of patients with chronic GVHD approximately one year
after transplantation. Bronchiolitis obliterans has been
reported to occur in 2% to 14% of AHSCT patients and has
a mortality rate of 50% (155). Late liver complications have
been described to include hepatitis B and hepatitis C infec-
tions, which may be asymptomatic or progress to fulminant
hepatitis or cirrhosis (156). Iron overload is diagnosed in up
to 88% of long-term survivors of AHSCT (157). Neurologic
toxic effects that may arise include leukoencephalopa-
thy, cerebellar ataxia, seizures, and motor spinal cord
syndromes.
CONCLUSION
AHSCT provides prolonged remission in many pa-
tients with hematologic diseases and cure in some
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patients. Complications such as acute and chronic GVHD,
infections and to a lesser extent SOS, remain major obstacles
for the success of AHSCT. Progress in prevention approaches
as well as advances in the conventional management of the
underlying malignancies, expansion of the donor pool
and the use of nonmyeloablative regimens have improved
the outcome of these patients. Lifelong observation and
screening is of utmost importance because of the late serious
complications that can develop in this patient population.
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